论文部分内容阅读
目的 :用癌基因和抑癌基因蛋白产物在乳癌中过表达 ,探讨与病理分级 ,肿瘤生物学行为和预后指标雌激素受体 (ER)表达的关系 ,为临床治疗及预后的判断提供客观参数。方法 :应用免疫组化 S- P法检查 4 8例乳癌中 P53,C- erb B- 2 ,PCNA和 ER表达水平。结果 :4 8例乳癌中 P53,C- erb B-2 ,PCNA和 ER阳性表达率分别为 54% ,4 3% ,52 %和 4 1.6 %。P53,C- erb B- 2随着组织分级增高呈递增趋势 , 级与 、 级间阳性率差异显著 (P<0 .0 5) ,与 PCNA表达存在平行关系 ,与 ER表达呈负相关趋势 ;伴有淋巴结转移组与无淋巴结转移组间也存在显著差异 (P<0 .0 5)。结论 :P53,C- erb B- 2过表达与淋巴结转移及预后有密切关系 ,可作为恶性程度及预后的可靠指标
OBJECTIVE: To over-express the oncogene and tumor suppressor gene protein products in breast cancer, and to explore the relationship with pathological grade, tumor biological behavior and prognosis indicators of estrogen receptor (ER) expression, and to provide objective parameters for clinical treatment and prognosis judgment . Methods : The expression of P53, C-erb B-2, PCNA and ER were detected in 48 breast cancer patients by immunohistochemical SP method. RESULTS: The positive expression rates of P53, C-erb B-2, PCNA, and ER in 48 breast cancers were 54%, 4 3%, 52%, and 41.6%, respectively. P53 and C-erb B-2 showed an increasing trend with increasing tissue grading, and the positive rate between grades and grades was significantly different (P<0.05). There was a parallel relationship with PCNA expression and a negative correlation with ER expression. There was also a significant difference between lymph node metastasis group and no lymph node metastasis group (P<0.05). Conclusion: Overexpression of P53 and C-erb B-2 is closely related to lymph node metastasis and prognosis. It can be used as a reliable indicator of malignancy and prognosis.